Silenseed, a leading RNAi-based therapeutics company, announced today (May 4, 2016) the publication of “Preclinical Safety Evaluation in Rats of a Polymeric Matrix Containing an siRNA Drug Used as a Local and Prolonged Delivery System for Pancreatic Cancer Therapy” Ramot Y, Rotkopf S, Gabai RM, Khvalevsky EZ, Muravnik S, Marzoli GA, Domb AJ, Shemi A, Nyska A.Toxicol Pathol. 2016 May 4. pii: 0192623316645860